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Introduction
Sitosterolemia (STSL), also known as phytosterolemia, is a rare autosomal recessive inherited sterol storage disorder characterized by increased levels of plasma plant sterols (PSs), including stigmasterol, campesterol, and, most abundantly, sitosterol [1] . STSL is caused by pathogenic variants in the genes of two adjacent ATP-binding cassette subfamily G members, i.e. members 5 and 8 (ABCG5 and ABCG8), which encode sterolin-1 and sterolin-2, respectively [2] . These proteins, which contain six transmembrane domains and an ATP-binding domain, travel as heterodimers to the apical membrane of the enterocyte and the canalicular membrane of the biliary tract, where they become full, active transporters of sterols, although they require ATP to function [2, 3] . Sterolins regulate the network of absorption and excretion of sitosterol and cholesterol. In enterocytes, they promote the flow of sitosterol back into the intestinal lumen and liver, and the excretion of sterols into bile [3] . Like those of other inherited thrombocytopenias (ITs), the prevalence of STSL is unknown, although one Asian individual with STSL was identified incidentally out of 2542 persons [4] . Clinical features of STLS usually include tendinous and cutaneous xanthomas, premature coronary atherosclerosis and derived complications, and arthritis or arthralgia [5] . These characteristics are shared with familial hypercholesterolemia (FH), so STSL may be misdiagnosed as homozygous FH, especially in pediatric patients [6, 7] . Unlike patients with FH, patients with STSL usually respond well to a low-cholesterol diet and/or bile acid sequestrants such as colestimide and colestyramine [6] . Hematologic abnormalities, e.g. hemolytic anemia (HA), iron deficiency anemia, macrothrombocytopenia (i.e. large platelets), abnormal bleeding, and/or splenomegaly, may coexist with other clinical features [8] . These hematologic problems have been occasionally reported as the only clinical symptoms in otherwise asymptomatic STSL patients [5, 8] . Combined macrothrombocytopenia and stomatocytosis, known as Mediterranean stomatocytosis/ macrothrombocytopenia, was initially described in Mediterranean migrants to Australia [9] . The diagnosis of STSL is usually delayed because many physicians are unfamiliar with its clinical picture [5] . This delay is important because, like patients with other ITs, non-diagnosed patients may be at high risk of receiving inappropriate treatment for a considerable period [8, 10] .
We report two novel ABCG5 variants causing syndromic macrothrombocytopenia in a Spanish family, in a case previously reported to be one of FH. We summarize the clinical and mutational landscape of STSL in relation to hematologic abnormalities, and propose some clinical indications for a PS assay and for molecular analysis.
Patients and methods
The propositus was a 46-year-old female referred to us with lifelong macrothrombocytopenia. Her medical history included palpebral surgery for xanthelasma on several occasions, and clinical suspicion of FH. Her paternal grandparents were first cousins. The patient suffered from arthralgia and mild ecchymosis after trauma. Examinations revealed no hepatosplenomegaly or clinically significant lymphadenopathy, but she presented with xanthelasmas (Fig. 1A) . Bleeding was of minor relevance, with an ISTH Bleeding Assessment Tool score of 1. Analysis of blood parameters showed the following: hemoglobin level, 13.3 g dL
À1
; reticulocytes, 2%; platelet count, 69.8 9 10 3 mm À3 . The mean platelet volume was 15.5 fL (Sysmex XE 2100; Roche, Basel, Switzerland). No biochemical abnormalities were found. Peripheral blood (PB) smears revealed abnormally shaped erythrocytes (22% stomatocytes) and giant platelets, some as large as the erythrocytes (Fig. 1B) . Platelet aggregation in response to ADP and ristocetin was normal. The levels of platelet glycoprotein (GP) Ib-IX and GPIIb-IIIa measured by flow cytometry were also normal (results not shown). Given the syndromic macrothrombocytopenia, the patient's DNA was screened for molecular variants in 71 candidate genes related to inherited platelet disorders (IPDs) by use of an established high-throughput sequencing (HTS) platform (MiSeq; Illumina, San Diego, CA, USA) and accompanying variant analysis [10, 11] . Serum PS and cholesterol levels were quantified with gas-liquid chromatography (GLC) [3] . Briefly, PSs and cholesterol were isolated following alkaline hydrolysis and extraction with organic solvent, and then analyzed with GLC in an Agilent 7890 chromatograph fitted with a flame detector (trimethylsilyl derivative; BSTFA 1%/TMCS in pyridine; Sigma, St. Louis, MO, USA) in a DB1701 (S&W Scientific, Folsom, CA, USA) column. Epi-coprostanol (Sigma) was used as the internal standard. Reference values were from individuals aged 1-60 years whose cholesterol metabolism was unaltered. The normal ranges (NRs) for sitosterol, campesterol, b-cholestanol and cholesterol were: < 10 lM, < 3 lM, 2.2-12.6 lM, and 1.7-6.6 mM, respectively.
The study was performed in accordance with the Declaration of Helsinki. The patient and healthy controls provided written informed consent.
Results and discussion
We report the clinical and molecular features, and treatment outcome, of a patient presenting with xanthelasmas who had been previously misdiagnosed with FH. Notably, her blood film showed prominent stomatocytes and giant platelets (Fig. 1 ). It should be emphasized that careful examination of the PB smear has been proposed as the most important aspect of the diagnostic approach to this disorder [12, 13] . Some authors have also suggested that platelet size should be reviewed in all patients with hypercholesterolemia [5] . HA and thrombocytopenia are hematologic abnormalities that are commonly encountered in daily practice; the coexistence of unexplained HA with stomatocytosis and macrothrombocytopenia should alert physicians to the possibility of STSL [14] . Nevertheless, these STSL-associated hematologic abnormalities are still not recognized by most physicians, and many STSL patients are not diagnosed until adulthood [12, 15] . In addition, STSL patients may suffer from long-term misdiagnosis of immune thrombocytopenia (ITP), Evans syndrome, or ITP secondary to arthritis. Consequently, many STSL patients are treated with useless or even harmful therapies, such as steroid therapy and/or splenectomy, as occurs with other misdiagnosed ITs [10, 12, 15] . For the molecular analysis of this patient, we used a novel HTS panel to simultaneously process a large number of genes involved in IPDs [10, 11] . The HTS test revealed novel compound heterozygote variations affecting exons 7 (c.914C>G; p.T305R) and 13 (c.1890delT; p.F630L fs8X) of ABCG5. As routine cholesterol measurement methods do not discriminate cholesterol from PSs, we used a specific GLC method [3, 12] to determine cholesterol and PS levels separately. The patient's cholesterol level was 2.7 mM, which was in the NR, owing to her previous treatment with statins. Measurements of plasma PS levels revealed high concentrations of sitosterol (668.2 lM), campesterol (169.6 lM), and b-cholestanol (30.7 lM). These findings confirmed the diagnosis of STSL in our patient. There was a striking delay of decades between the onset of symptoms and the STLS diagnosis. Long delays in providing a definitive diagnosis have also been reported in other cases of STLS [12] . Such delays are not inconsequential, as they can lead to inappropriate clinical management, including delayed PS restriction and administration of sterol absorption inhibitor [6] , and a subsequent risk of advanced atherosclerotic cardiovascular disease and poorer clinical outcome in affected patients. Following her definitive STLS diagnosis, our patient began ezetimibe therapy, which effectively decreased the plasma levels of total cholesterol and LDL cholesterol [16] . Although ezetimibe has been shown to improve thrombocytopenia in ABCG5-knockout mice, this benefit has not been consistently found in humans [17, 18] . After 4 months of ezetimibe treatment, sitosterol levels were reduced by 30% (473.1 lM), whereas cholesterol (2.4 mM), campesterol (156.3 lM) and b-cholestanol (23 lM) levels remained similar. However, our patient still showed moderate macrothrombocytopenia (platelet count: 80.9 9 10 3 mm À3 ).
Since the first description of this disorder in 1974, < 100 related cases have been found worldwide [1, 4, 12] . To our knowledge, only 25 unrelated STSL patients presenting with hematologic abnormalities at the time of diagnosis have been reported, some of whom had been previously misdiagnosed with ITP or HA, and had therefore undergone splenectomy (Table 1 ). Most of these described families were consanguineous. Although consanguinity was detected in this pedigree, the patient had a compound heterozygosis, so the family relationship is unlikely to be relevant here (Fig. 2A) . The mechanism by which sitosterol accumulation might negatively affect platelet structure and function is not well understood. Whereas some authors have described decreased platelet activation responsiveness in animal models of sitosterolemia [19] , others have identified platelet hyperactivation, reduced a IIb b 3 surface expression, loss of GPIba-FlnA linkage, and microparticle formation [17] . As in previous STLS cases (Table 1) [12] , our patient showed almost negligible bleeding diathesis and no platelet defects with respect to aggregation or the expression of major GPs.
The molecular pathology involved in STSL affects ABCG5 and ABCG8 [20, 21] . These two genes probably evolved from a common ancestral gene by a tandem duplication and inversion event. The intergenic region between ABCG5 and ABCG8 is very small (< 160 bases) and contains no conserved TATA motif(s), suggesting that transcriptional factors help to regulate this locus [22] . Moreover, mutational founder effects underlie many of the cases, suggesting that this disease has been present for many generations, perhaps for > 4000 years [23] . However, despite the close proximity and homology of ABCG5 and ABCG8, considerably more polymorphisms are present in ABCG8 than in ABCG5 [23] . Caucasians (mostly of northern European origin) frequently carry mutations in ABCG8, whereas Chinese, Japanese and Indian patients often have mutations in ABCG5 (Table 1 ) [6] . Among these, 35% and 65% feature homozygous or compound heterozygous variants in ABCG5 and ABCG8, respectively [6, 24] . Some heterozygotes showed higher CHD, coronary heart disease; F, female; FHC, familial hypercholesterolemia; HA, hemolytic anemia; LTA, light transmission aggregometry; M, male.
© 2017 International Society on Thrombosis and Haemostasis than normal PS levels, but these were still substantially lower than those in homozygotes [25] . Twenty-eight variants have previously been reported in the ABCG5 gene (Table 1; Fig. 3 ), and only six variants are present in more than one patient. Several of these are nonsense variants (eight) or frameshift variants (three), or affect the splicing site (eight) or code for truncated polypeptides (two). Others are missense variants (seven) that interfere with the formation of stable ABCG5-ABCG8 heterodimers and their trafficking out of the endoplasmic reticulum [6, [26] [27] [28] [29] (Fig. 3) .
Only 11 of the 28 reported variants are associated with macrothrombocytopenia (Fig. 3) . The patient reported here carries two variants affecting exons 7 and 13 of the ABCG5 gene. The former, c.914C>G; p.T305R, a rare single-nucleotide polymorphism (SNP) (rs143740796) with a minor allele frequency of 0.00002486 (http://exac.b roadinstitute.org), is predicted to be pathogenic by in silico models (SIFT, POLYPHEN-2, MUTATIONASSESSOR, and MUTATIONTASTER). This SNP affects highly conserved residues at the N-terminal domain, in the intracytoplasmic region of the ABCG5 protein [3] . The remarkable degree of conservation of the STSL locus in fish, amphibians, rodents and humans suggests that the polymorphic changes may have a dramatic effect on function [3] . The second genetic variant in the patient is a novel microdeletion in exon 13 (c.1890delT; p.F630L fs8X) that causes replacement of phenylalanine by leucine at amino acid position 630, producing a frameshift and stop codon at amino acid 638 (Fig. 2B) . The heterogeneous landscape of STSL may be related both to other genetic factors and to environmental conditions, which can modify gene expression or sterol absorption [15] . For example, an olive oil-rich diet contributes to elevated PS levels in blood [15] . Phenotypic heterogeneity could also arise by gene conversion that restores the wild-type sequence of the maternal or the paternal allele, converting the compound heterozygous condition to a simple heterozygous one, in the form of mosaicism [26] .
The underlying mechanism responsible for the hematologic abnormalities observed in some patients with STSL is most likely the accumulation of circulating PSs in blood cell membranes, leading to their abnormal morphology and function [29] . Thus, excess PS levels promote membrane stiffness and predispose to rupture. Likewise, PS enrichment in platelet membranes might affect their size, number, and function, which could be related to bleeding episodes [29] . These hypotheses were suggested to explain the behavior of ABCG5-deficient and ABCG8-deficient mice [17, 19] . In humans, however, only some patients with STSL show hematologic abnormalities. Moreover, some variants, such as R419H and R446X (ABCG5), are associated with thrombocytopenia, although not in all patients, implying that unknown mechanisms are also involved (Table 1 ). Our screening of 71 genes related to IPD yielded no candidate variants other than those mentioned above. It has been suggested that whole-exome or whole-genome analysis might identify new genetic determinants that predispose patients to having these clinical conditions.
In summary, we have characterized the first case of STSL in a Spanish patient by using a novel HTS multigenic platform for an initial molecular survey. A definitive diagnosis of STSL based on the measurement of serum PS levels prompted the use of ezetimibe therapy, which effectively reduced serum PS levels. It is essential to suspect and correctly diagnose this controllable disorder to ensure its proper management, and prevent cardiovascular diseases. 
